NCT01723670View on ClinicalTrials.gov

Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

CHF 5074 1x

oral tablet, 1x, once a day for 24 months

DRUG

CHF 5074 2x

oral tablet, 2x, once a day for 24 months

DRUG

Placebo

oral tablet,once a day for 24 months

Sponsors

Lead Sponsor

CERESPIR
All Listed Sponsors
lead

CERESPIR

INDUSTRY